Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
Go back to Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes| Abbott Laboratories (NYSE: ABT) | Delayed: 106.05 -2.28 (2.1%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $108.33 | 52 Week High | $46.38 | |||
| Open | $108.36 | 52 Week Low | $36.00 | |||
| Day High | $108.39 | P/E | 70.70 | |||
| Day Low | $105.24 | EPS | $1.50 | |||
| Volume | 5,508,575 | |||||
